Exelixis (EXEL) Convertible Debt (2010 - 2017)
Exelixis (EXEL) recorded quarterly Convertible Debt of $113.3 million in Q1 2017, up 39.09% quarter-over-quarter from $81.5 million in Q3 2016, and down 59.68% on a YoY basis from $281.2 million in Q1 2016.
Exelixis (EXEL) Convertible Debt (2010 - 2017) Analysis & Trends
Exelixis' Convertible Debt history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- In Q1 2017, Convertible Debt fell 59.68% year-over-year to $113.3 million; the TTM figure through Mar 2017 stood at $113.3 million (down 59.68% YoY), while the FY2015 annual figure was $337.9 million, up 51.12% from the prior year.
- Convertible Debt was $113.3 million for Q1 2017 at Exelixis, up from $81.5 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $337.9 million in Q4 2015 to a low of $81.5 million in Q3 2016.
- Historically, Convertible Debt has averaged $240.1 million across 5 years, with a median of $255.1 million in 2013.
- The sharpest annual moves came in 2013 and 2016: Convertible Debt jumped 182.83% in 2013, then slumped 72.6% in 2016.
- A 5-year view of Convertible Debt shows it stood at $301.6 million in 2013, then dropped by 25.84% to $223.6 million in 2014, then soared by 51.12% to $337.9 million in 2015, then plunged by 75.89% to $81.5 million in 2016, then soared by 39.09% to $113.3 million in 2017.
- The last three Convertible Debt figures came in at $113.3 million (Q1 2017), $81.5 million (Q3 2016), and $288.6 million (Q2 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 113.35 Mn |
| Sep 30, 2016 | 81.49 Mn |
| Jun 30, 2016 | 288.56 Mn |
| Mar 31, 2016 | 281.16 Mn |
| Dec 31, 2015 | 337.94 Mn |
| Sep 30, 2015 | 297.44 Mn |
| Jun 30, 2015 | 291.23 Mn |
| Mar 31, 2015 | 284.36 Mn |
| Dec 31, 2014 | 223.63 Mn |
| Sep 30, 2014 | 177.96 Mn |
| Jun 30, 2014 | 173.64 Mn |
| Mar 31, 2014 | 261.41 Mn |
| Dec 31, 2013 | 301.55 Mn |
| Sep 30, 2013 | 248.71 Mn |
| Jun 30, 2013 | 242.46 Mn |
| Mar 31, 2013 | 236.39 Mn |
| Dec 31, 2012 | 291.83 Mn |
| Sep 30, 2012 | 239.24 Mn |
| Jun 30, 2012 | 85.86 Mn |
| Mar 31, 2012 | 83.58 Mn |